Published in Clin Cancer Res on April 10, 2012
Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle (2012) 1.41
CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One (2013) 1.25
CD133: a stem cell biomarker and beyond. Exp Hematol Oncol (2013) 1.24
CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol (2013) 1.15
New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int (2014) 1.08
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget (2014) 0.92
Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives. World J Gastroenterol (2014) 0.90
CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis. Mol Cancer (2014) 0.87
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population. Mol Cancer (2016) 0.82
Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer (2017) 0.80
Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer. Cancer Biol Ther (2016) 0.79
Lgr5 is a potential prognostic marker in patients with cervical carcinoma. Int J Clin Exp Pathol (2015) 0.77
Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneity. Mol Cell Oncol (2015) 0.77
Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran. Gastroenterol Hepatol Bed Bench (2016) 0.75
Prognostic value of CD133 caused by mutant K-Ras and B-Raf--letter. Clin Cancer Res (2012) 0.75
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 7.05
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature (2013) 4.83
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature (2012) 4.53
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med (2013) 4.22
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers. EMBO J (2012) 3.70
Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol Cell Biol (2008) 3.02
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell (2009) 2.93
The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol (2012) 2.83
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65
Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature (2011) 2.59
Colon cancer stem cells: promise of targeted therapy. Gastroenterology (2010) 2.58
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev (2008) 2.20
Cancer stem cell niche: the place to be. Cancer Res (2011) 2.14
The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res (2010) 2.12
Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell (2013) 2.10
APRIL modulates B and T cell immunity. J Clin Invest (2002) 2.07
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
Domain-wide regulation of gene expression in the human genome. Genome Res (2007) 1.86
Working memory retention systems: a state of activated long-term memory. Behav Brain Sci (2003) 1.85
The three-dimensional structure of human interphase chromosomes is related to the transcriptome map. Mol Cell Biol (2007) 1.82
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell (2010) 1.81
Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell (2011) 1.80
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res (2010) 1.79
Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging. Stem Cells (2015) 1.75
Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res (2010) 1.71
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A (2009) 1.66
Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem (2009) 1.62
Continuous clonal labeling reveals small numbers of functional stem cells in intestinal crypts and adenomas. Cell Stem Cell (2013) 1.56
Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells (2012) 1.55
Activation of the granzyme pathway in children with severe respiratory syncytial virus infection. Pediatr Res (2008) 1.54
Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res (2008) 1.50
The TNF family member APRIL dampens collagen-induced arthritis. Ann Rheum Dis (2012) 1.49
Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A (2012) 1.46
Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res (2010) 1.46
OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol (2006) 1.39
Extensive polycistronism and antisense transcription in the mammalian Hox clusters. PLoS One (2007) 1.36
Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res (2008) 1.36
APRIL promotes B-1 cell-associated neoplasm. Cancer Cell (2004) 1.34
Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles. BMC Genomics (2005) 1.34
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
Molecular identification and targeting of colorectal cancer stem cells. Oncotarget (2010) 1.33
IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle (2007) 1.29
Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett (2005) 1.28
ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer (2007) 1.28
Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. Cancer Res (2005) 1.26
Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. Gene (2004) 1.25
Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer (2003) 1.21
The role of the MEIS homeobox genes in neuroblastoma. Cancer Lett (2003) 1.19
Prevalence and patterns of morphological abnormalities in patients with childhood cancer. JAMA (2008) 1.18
Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors. PLoS Comput Biol (2011) 1.18
The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene (2004) 1.18
Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer (2009) 1.18
Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem (2007) 1.18
Granzymes at a glance. J Cell Sci (2006) 1.18
Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol (2002) 1.17
Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. Eur J Cancer (2007) 1.15
LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol (2012) 1.12
Efficient double fragmentation ChIP-seq provides nucleotide resolution protein-DNA binding profiles. PLoS One (2010) 1.12
Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs (2010) 1.11